Help slow the progressive damage of arthritis

Prescribing Adequan® i.m. (polysulfated glycosaminglycan) at the first signs of DJD may help horses enjoy greater mobility over a lifetime.1,2,3 DJD can affect horses of any age and gets worse if left untreated, so it’s important to educate your clients and identify and address it early to help preserve their horse’s joint health.

Make mobility a vital sign by talking to your clients about DJD.

Nothing works like
Adequan i.m.

Adequan i.m. is the only FDA-approved injectable PSGAG that is proven to actually treat DJD, not just its symptoms—and it’s still the only joint treatment of its kind. For 30 years, veterinarians, horse owners, riders and trainers have made Adequan i.m. a top choice for helping to extend a horse’s mobility span.

See how Adequan i.m. works


Here’s how Adequan i.m. was proven to work within equine joints


lameness by reducing swelling associated with arthritis


inflammation by restoring synovial lubrication


the production of new cartilage


harmful enzymes that attack cartilage and synovial fluid


the disease process that leads to loss of cartilage

After just one intramuscular injection, Adequan i.m. quickly reaches the horse’s joints, where it goes to work fast and keeps working for up to four days to deliver relief.4 Hyaluronic acid (HA) levels nearly doubled at 48 hours with significant increases noted from 24 to 96 hours.4 The clinical significance of these results is unknown.

Follow recommended dosing for maximum benefit

When administered according to the recommended dosing schedule and has demonstrated Adequan i.m. not only reaches joints quickly, it also helps to protect and renew joint mobility1 without the injection-site, blood clotting or efficacy issues of other joint treatments.


Peak levels achieved
in the joints within

2 hours

HA nearly
doubles at


The clinical significance of the results is unknown.4
Detected in cartilage and
subchondral bone up to


Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.

FDA approval means you can prescribe with confidence

Adequan i.m. is an FDA-approved veterinary drug, which means it’s backed by clinical data that demonstrated it has passed each stage of the approval process and met the requirements for drug safety and efficacy. Non-approved alternatives don’t have the same requirements.

There is no generic Adequan i.m.

Adequan i.m. is unique because there is no generic version of the drug. While other products may claim to be the same as Adequan i.m., the reality is that it’s the only FDA-approved PSGAG for the intramuscular treatment of non-infectious degenerative joints disease of the carpal and hock joints in horses.

This is not a complete list of all products available.

“Adequan has survived the test of time. The only reason for that is its effect. It’s efficacious. It works. That’s why clients still request Adequan and that’s why I still recommend it.”

Robert P. Bosley

DVM, Equine Sports Medicine Group
Dr. Bosley is a paid consultant for American Regent Animal Health.

Talk to your clients about Adequan i.m.

Find handy, informative resources and tools to help you educate your clients about their horse’s joint health and and ways to improve DJD diagnosis and treatment.


Palomino horse wearing a Western bridle waits for a show to start
Veterinarian strokes a horse's face during a check up
Chestnut horse wearing a Western bridle standing in front of a fence

Keep up on treating equine arthritis with Adequan i.m.

Take advantage of free, fully accredited continuing education courses to learn how to identify, diagnose and treat degenerative joint disease.


Stay informed on Adequan i.m.

Be the first to hear about important news and product information.


  1. Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57.
  2. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.
  3. Adequan® i.m. (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.
  4. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.

Advancing joint care for dogs & horses

For more than 30 years, veterinarians have relied on the American Regent Animal Health family of products to provide solutions that help support joint health in their patients. Our mission is to champion the long-term well-being and mobility of animals, from top athletes to family companions.